Navigating Difficult Conversations in Cancer Pain Management
Difficult conversations in cancer pain management should include core values and principles, setting realistic expectations, and building the patient-client relationship from the very beginning.
Belantamab Mafodotin Plus Vd Significantly Improves PFS in Relapsed/Refractory Multiple Myeloma
February 9th 2024Patients with relapsed/refractory multiple myeloma treated with belantamab mafodotin plus bortezomib and dexamethasone experienced a significant improvement in PFS compared with daratumumab plus bortezomib and dexamethasone.
Second-Line Fruquintinib Plus Paclitaxel Significantly Improves PFS in Advanced Gastric Cancer
February 8th 2024Patients with advanced gastric cancer treated with second-line fruquintinib/paclitaxel experienced significant improvements in progression-free survival but not overall survival when compared with paclitaxel alone.
Assessing Subsequent Therapies in mHSPC Confirms OS Benefit From Darolutamide
February 4th 2024Subsequent therapies in patients with metastatic hormone-sensitive prostate cancer who were censored from primary overall survival follow-up from the ARASENS trial, according to a post hoc sensitivity analysis, confirmed the overall survival benefit derived from darolutamide plus androgen deprivation therapy and docetaxel.